And for a number: Based on the strength of the Phase 2b data,...

And for a number:

Based on the strength of the Phase 2b data, the solid scientific rationale for VEGF-C/D inhibition, and the track record of Opthea’s leadership in successfully guiding retinal drugs to market, a rough estimate for the likelihood of success might stand at around 70%. This figure is not an exact statistic but rather a reasoned guess that takes into account the more favourable indicators (robust Phase 2 results, strong management, and a well-defined mechanism of action) balanced against the inherent unpredictability of clinical research